Home/Pipeline/SCO-201

SCO-201

Solid Tumors

Pre-clinicalOn Hold

Key Facts

Indication

Solid Tumors

Phase

Pre-clinical

Status

On Hold

Company

Scandion Oncology

About Scandion Oncology

Scandion Oncology aimed to address the critical unmet need of cancer drug resistance by developing adjunctive, biomodulating therapies. Its lead asset, SCO-101, advanced to Phase 2 trials in metastatic colorectal cancer (mCRC) and Phase 1b in pancreatic cancer, targeting the ABCG2 efflux pump and UGT1A1 enzyme. Despite achieving clinical milestones, the company's strategic path to partnership or further funding was not realized, leading to a shareholder decision to liquidate the company in early 2025 and distribute remaining assets.

View full company profile

Therapeutic Areas

Oncology

Other Solid Tumors Drugs

Drug	Company	Phase	Status
APVO603	Aptevo Therapeutics	Preclinical	Active
APVO711	Aptevo Therapeutics	Preclinical	Active
Platform-derived Immunotherapy	GenCirq	Pre-clinical	Active
SP-2-225	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
SP-1-161	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
HBM1020	Harbour BioMed	Phase 1	Active (Global)
HBM7022	Harbour BioMed	Phase 1	Out-Licensed
HBM9033	Harbour BioMed	Discovery	Out-Licensed
Undisclosed Whole Cell Vaccine Program(s)	Neuvogen	Pre-clinical	Active
SY-5609	Syros Pharmaceuticals	Phase 1/2	Discontinued
Not Specified (TCR Therapy)	T-Cure Bioscience	Phase 1	Active
B7-H3 Program	Ocean Biomedical	Discovery	Active